A carregar...
Management of adverse events during cyclin-dependent kinase 4/6 (CDK4/6) inhibitor-based treatment in breast cancer
Cyclin-dependent kinase (CDK) 4/6 inhibitors have shown great results in numerous clinical trials and have improved the clinical outcome for patients with hormone-receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer significantly. To date, three CDK4/6 inhibito...
Na minha lista:
| Publicado no: | Ther Adv Med Oncol |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
SAGE Publications
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6122233/ https://ncbi.nlm.nih.gov/pubmed/30202447 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835918793326 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|